Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has shared an announcement.
Clarity Pharmaceuticals has announced the imaging of the first patient in its Phase III AMPLIFY trial, which aims to evaluate the effectiveness of 64Cu-SAR-bisPSMA PET/CT in detecting biochemical recurrence of prostate cancer. This trial is pivotal for Clarity’s plans to submit a New Drug Application for the diagnostic agent, which has shown promising results in earlier studies by identifying lesions earlier and more accurately than current standard-of-care imaging. The trial will enroll approximately 220 participants across the US and Australia, potentially enhancing the company’s market positioning by addressing limitations in current PSMA PET diagnostics and improving accessibility for prostate cancer detection.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve treatment outcomes for cancer patients. The company specializes in targeted copper theranostics, utilizing proprietary sarcophagine technology to securely hold copper isotopes for diagnostic and therapeutic purposes.
Average Trading Volume: 2,768,192
Technical Sentiment Signal: Sell
Current Market Cap: A$710.2M
See more data about CU6 stock on TipRanks’ Stock Analysis page.